Cardiac troponin I and cardiac troponin T are nowadays the criterion biomarkers for the laboratory diagnosis of acute myocardial infarction due to their very high sensitivities and specificities for myocardial injury. However, still many aspects of their degradation, tissue release and elimination from the human circulation are incompletely understood. Myocardial injury may be caused by a variety of different mechanisms, for example, myocardial ischaemia, inflammatory and immunological processes, trauma, drugs and toxins, and myocardial necrosis is preceded by a substantial reversible prelethal phase. Recent experimental data in a pig model of myocardial ischaemia demonstrated cardiac troponin release into the circulation from apoptotic cardiomyocytes as an alternative explanation for clinical situations with increased cardiac troponin without any other evidence for myocardial necrosis. However, the comparably lower sensitivities of all currently available imaging modalities, including cardiac magnetic resonance imaging for the detection of particularly non-focal myocardial necrosis in patients, has to be considered for cardiac troponin test result interpretation in clinical settings without any other evidence for myocardial necrosis apart from increased cardiac troponin concentrations as well.
Introduction
Questions relating to the mechanisms by which cardiomyocytes release biomarkers and, more recently, cardiac troponins (cTns) have been controversial for years. It has been the general consensus that increases of myocardial injury biomarkers in peripheral venous blood should be a marker of myocardial necrosis, although there are still no
How is cardiac troponin released from injured myocardium?
consensus approaches to the laboratory diagnosis or the biochemical definition of cell necrosis and/or apoptosis. 1, 2 The common thinking supported by clinical evidence, that is, limited functional recovery after loss of human myocardium and a very low rate of primary human cardiac tumours, has been that in contrast to skeletal muscle cardiomyocytes cannot undergo repair or be replenished, and consequently that the capacity of the adult heart to regenerate functional myocardium is extremely limited or absent. In the 1970s creatine kinase was shown to be released in baboons in response to short periods of induced coronary ischaemia, 3 which were assumed to be inadequate to induce cardiomyocyte death. However, subsequently Ishikawa et al. reported in similar experiments that when one searched hard enough with electron microscopy there was indeed evidence of necrosis when creatine kinase was released in experimental animals. 4 This was supported by the finding that mitochondrial creatine kinase, which is more specific for cell death, was also released whenever systemic increases in creatine kinase were observed in these animals. 4 In addition, there is experimental evidence, obtained during the last 15 years, which supports a new dogma, that is, that the adult mammalian heart is capable of limited renewal throughout life by cardiomyocyte mitosis and/or cellular replacement originating from stem cells. [5] [6] [7] These issues have become more important for the laboratory diagnosis of myocardial injury because of clinical observations of cTn increase in several settings, such as cTn release in healthy asymptomatic athletes after extraordinary endurance exercise or after reversible myocardial ischaemia during myocardial scintigraphy, or after atrial pacing, or in response to dobutamine stress testing, [8] [9] [10] [11] which lead one to question whether myocardial necrosis is always the cause of cTn release. These observations could support the concept that there are alternative mechanisms for cTn release. cTn assays with an even higher analytical sensitivity than currently available highsensitivity cTn assays (so-called 'ultra-sensitive' assays) are expected to be available for routine testing in Europe in the near future, and with that there will be an appreciation of even more situations where the release of cTn occurs in the absence of what we currently think would be myocardial necrosis.
This review summarizes the evidence for alternative mechanisms for cTn release and tries to put it into the context of test result interpretation of cTn assays with very high analytical sensitivity in daily routine. These issues are of potential importance for normal range studies, the definition of unstable angina or medical decision limits for the diagnosis of myocardial injury, including myocardial infarction.
Clinical scenarios suggesting alternative mechanisms for cardiac troponin release
A variety of clinical observations (see Table 1 ) suggest that cTn release occurs in situations where myocardial necrosis is unlikely. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] For example, many healthy individuals have elevated cTn after extreme endurance exercise. [8] [9] [10] Postrace acute reversible dysfunction of the right ventricle but not the left ventricle has been described. [8] [9] [10] There was no close correlation (0.49) between post-race cTn I (cTnI) concentrations and right ventricular ejection fraction decreases. 8 Post-race cTn elevations usually return to within the normal range within 24 hours [8] [9] [10] and are not associated with worse long-term prognosis, 9,10 which might lead some to suggest they are not associated with myocardial necrosis or even myocardial cell death. However, there are data suggesting that some endurance athletes can develop cardiac comorbidities in the long term, such as cardiac structural remodelling with signs of fibrosis of the interventricular septum and a somewhat lower right ventricular ejection fraction 9 or atrial fibrillation, 18 in response to repetitive exercise-induced myocardial injury. 9 Similarly, there are data documenting cTn release after rapid atrial pacing. 12 These cTn increases detected with high-sensitivity cTn (hs-cTn) assays were seen both in the coronary sinus and in the systemic circulation in individuals with coronary artery disease (CAD), in those who develop lactate accumulation as a sign of myocardial injury but also in normals, causing overlap in terms of the cTn response between both groups. 12 In a recent study of the use of cTn to predict positive stress tests one sees such overlap as well, 13 which was in contrast to a prior, smaller study which reported significant difference in the cTnI response in patients with and without reversible myocardial ischaemia. 11 Therefore, the change in cTn concentration in response to a stress test cannot be used to diagnose significant CAD. In addition, recent data have indicated that the infusion of dobutamine causes increases in cTn as well, both in those with significant CAD and in putatively 
Pathophysiology of cardiac troponin release from injured myocardium -an update
There is substantial evidence that in response to skeletal muscle stress, skeletal muscle myocytes may die. 19, 20 It appears that these cells are replaced by differentiation of resident myoblasts that repair the injured skeletal muscle, 20 and indeed this is thought to be a way by which increased muscle strength can be induced. However, commonly it has been believed that in contrast to skeletal muscle the heart is a post-mitotic organ and cardiac muscle cannot repair and replenish injured cells. Thus, proteins being extruded from cardiomyocytes has been interpreted always as a sign of cell necrosis. 1 Complete functional recovery, however, at least of the neonatal human heart after myocardial infarction, has been reported, 6 and even evidence for continuing limited cardiac renewal of the adult human heart has been obtained during recent years as well. 5, 7 The mitosis rate of adult human cardiomyocytes in the healthy heart is only about 0.5% to 1% per year and the majority of cardiomyocytes are never exchanged. 5 Initial promising data on human cardiomyocyte regeneration from resident and extra-cardiac stem/progenitor cells have been reported, but could not consistently be confirmed. 7 Nonetheless, there appears to be some limited cardiomyocyte turnover and renewal under normal and diseased conditions in humans mainly by cardiomyocyte proliferation throughout life, and the cardiomyocyte renewal rate may be higher after injury. 7 Feng et al. reported in an experimental study that acute increases in preload, in the absence of ischaemia, lead to intramyocardial cTnI proteolysis and release of cTnI, a process that could be blocked by antibodies to calpain, 21 which is an enzyme that is essentially involved in intramyocardial troponin degradation. Preload-induced cardiomyocyte calcium entry and cTnI proteolysis may lead to stretch-induced cardiomyocyte apoptosis with cTnI release, which might explain cTn increase in patients with chronic non-ischaemic cardiomyopathy, where necrosis might not be expected although increased cTn is detected by high-sensitivity assays. 15 However, it has been thought that the proteins from cells dying due to apoptosis were degraded within tissues so they should not be detected in the peripheral systemic circulation. 1, 2 More recent experimental evidence in response to brief episodes of myocardial ischaemia in a pig model, however, demonstrates the contrary. 22 The mid-left anterior descending coronary artery was occluded for 10 minutes, a period which was thought from previous experiments to be an insult that would not cause myocardial necrosis. cTn release was investigated using an assay for porcine cTnI. These investigators documented substantial cTn increases in response to 10 minutes of occlusion and subsequent reperfusion over a period of 24 hours. Surprisingly, cTnI increases were -in contrast to reperfused acute myocardial infarctions -delayed and not immediate as one might think would be the case if there was an early releasable pool that could be quickly mobilized. The regular histological workup of these pig hearts revealed no evidence for myocardial necrosis; instead evidence for isolated, focal apoptosis of cardiomyocytes was found. 22 A limitation of these experiments was that apoptosis was claimed instead of being based on electron microscopy morphological findings only on the basis of standard biochemical methods (i.e. terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling -positive nuclei and immunostaining for active caspase-3), which have also been criticized for lack of sensitivity and specificity for apoptosis. 2 Therefore, to overcome this the diagnosis of 'apoptotic cardiomyocytes' required that cardiomyocytes stained positive with both biochemical methods. Ideally, however, a morphological workup of the hearts using electron microscopy would have been necessary to undoubtedly prove cardiomyocyte apoptosis and the absence of cardiomyocyte necrosis. 2 But this is obviously very labour intensive and difficult to perform in such kinds of experiments.
Nonetheless, based on these results apoptosis may be considered as a mechanism for cTn release from injured myocardium. Low normal myocardial cell turnover by intrinsic apoptosis could contribute to the observation that healthy subjects have detectable hs-cTn in peripheral venous blood. In response to myocardial injury by myocardial ischaemia and/or increase in myocardial wall stress it seems reasonable to assume that cTn could be released into the circulation in the absence of myocardial necrosis from an extrinsically enhanced apoptosis rate in myocardium as well.
However, the release of myocardial proteins such as cTn may not always require myocardial cell death. Experimental evidence suggests a number of possibilities for the extrusion of proteins from reversibly injured cardiomyocytes in the absence of cell death, including transient increases in cell permeability due to cell wounds, formation and the release from membranous blebs or microparticles (see Figure  1) . 1, [23] [24] [25] Apparently viable cardiomyocytes in Petri dishes or in animal models exchange macromolecules over the plasma membrane. 26, 27 This macromolecular exchange is higher if cardiomyocytes contract, are stretched by external forces, are challenged by beta-adrenergic stimulation, or after limited ischaemia of cardiomyocytes. [27] [28] [29] It appears that dystrophin complexes stabilize the membrane by forming links between the contracting sarcomere and the extracellular matrix. 29 Cells seem to be surprisingly resilient and repair membrane holes larger than 10 µm 2 within seconds, in a process called cell wound repair. The molecular details of this process are still unclear. 29 By contrast, cell fragmentation and sarcolemmal disruption with consecutive massive release of intracellular molecules into the interstitial space is believed to indicate morphologically the 'point of no return' of cell injury, that is, necrosis (see Figure 1) . Intact cTnI can be released from cultured viable cardiomyocytes by stimulation of stretch-responsive integrins. 30 However, reported experimental results on the release of cTn from attempts to reversibly injure cultured cardiomyocytes are conflicting, depending on cell type, experimental design and method used for the assessment of cell necrosis. 2 Finally, clearance changes may be responsible for some elevations of cTn as well. We are just starting to appreciate the complexity of cTn release and clearance. The complex physiology, biochemistry and pathophysiology of the cTn complex have been reviewed in detail recently. [32] [33] [34] In brief, initially, small (approximately 5% of total content), 'cytosolic' cTnI and cardiac troponin T (cTnT) pools have been reported in myocardium. 35, 36 But after considering preparation protocols used and the poor solubility of cTnI and cTnT in hydrophilic sarcoplasma, a more appropriate term is probably 'a loosely with finite affinity bound, rapidly releasable pool', which can be released from injured myocardium without extensive degradation of the myofilaments. 37 When not incorporated into myofilaments, for example, cTnT is rapidly degraded (e.g. by caspase or µ-calpain) within cardiomyocytes to avoid toxic effects. 21, 33, 38 These cytoplasmatic calpains are rapidly activated with myocardial injury by increased cytoplasmatic calcium. This process also activates phospholipases and endonucleases. By contrast, lysosomes are stable within the first 3-4 h after onset of cell injury, and, therefore, lysosomal enzymes are not involved in early degradation of structurally bound proteins. pH dependent dissociation of the troponin complex could be another important factor for early cTn release from injured myocardium. The pathophysiological role of limited intramyocardial proteolysis of cTn by caspase and calpain could be that cTns are involved in changing the sensitivity of cardiac muscle to declines in intracellular pH, and thus this may also be an early specific functional adaptive response to myocyte injury rather than just simple destructive breakdown leading to impaired myocardial function. 30 In contrast to cytosolic proteins, the release of structurally bound molecules, including cTns, requires both a leaky plasma membrane and dissociation from or degradation of cellular structures, such as the contractile filaments, which is a slow process. Thus, early cTn release may be due to its susceptibility to degradation by cytosolic proteases. Persisting cTn increases are more likely due to irreversible myocardial injury. On the other hand, those cTn increases that are shorter lived, as found in athletes after endurance exercise, [8] [9] [10] would be consistent with reversible cardiomyocyte injury as well. A critical issue for clinical practice will be the data based definition of 'short-lived' elevations (e.g. return to normal within 24 h in the absence of known baseline values).
Most proteins released from injured myocardium, including cTns, appear to be catabolized in tissues with a high metabolic rate, such as the liver, pancreas, kidneys or by receptor-mediated endocytosis in the reticuloendothelial system. Thus, in cases of impaired clearance from blood (e.g. renal failure, hypothyroidism) prolonged biomarker increases may be found or higher baseline values may be seen. Something similar seems to be the case for cTnT and cTnI. Once cTnT and cTnI reach the circulation, they are initially cleared with a half-life of 0.5 h in dogs and rats. 39 As cTn drops to lower concentrations such as those often observed in patients with stable cTn elevations recent data suggest that cTnT clearance becomes slower and more renal dependent. 40 Although intact cTnT is too large for glomerular filtration, smaller, circulating, degraded cTn fragments which are predominantly found in blood after myocardial injury would be small enough for glomerular filtration. 40 However, local degradation and tubular reabsorption could preclude the detection of cTnT and cTnI in urine. Nonetheless, at high cTnT concentrations (e.g. after acute myocardial infarction) extra-renal cTnT clearance dominates, but at low concentrations (e.g. patients with chronic cardiac diseases) renal clearance appears to dominate based on experiments where renal perfusion was reduced. 40 At these low steady-state concentrations cTnT levels are roughly twice as high if kidney function is reduced by 50%. 40 However, other multifactorial mechanisms, which already have been summarized by our group recently, 41 also contribute to the cTnT elevations seen in patients with chronic renal failure as well.
Potential clinical implications
There are a variety of causes of myocardial injury (see Table 2 41,42 ) but, nonetheless, cTn elevations, which are difficult to explain clinically, are frequently seen in daily routine. An algorithm for the work-up of increased cTn concentrations that do not fit to the clinical presentation has been recently published by our group; 41 primarily analytical interferences have to be ruled out and myocardial injury has to be confirmed by imaging modalities, including cardiac magnetic resonance imaging (MRI). However, the comparably lower sensitivities of all currently available imaging modalities, including cardiac MRI, for the detection particularly of non-focal myocardial necrosis has to be considered for cardiac troponin test result interpretation in patients without any other evidence for myocardial necrosis apart from increased cTn concentrations. It was reported in an experimental study of coronary microembolization in minipigs that the detection limit of cardiac MRI for focal myocardial lesions is 5% of myocardium per slice at histological examination. 16 In a clinical study on cTnI release in patients undergoing elective, complex percutaneous coronary intervention (PCI) even very small periprocedural late gadolinium enhancement (>0.3 g corresponding to >0.4% of total left ventricular mass) could be reliably detected by cardiac MRI. 43 However, the correlation between post-PCI cTnI concentration measured with a standard sensitive cTnI assay and MRI signs of myocardial necrosis was only moderate (r = 0.64). Table 2 . Conditions related to acute myocardial injury or chronically increased cardiac troponin concentrations.
Type 1 AMI:
Caused by acute coronary plaque rupture or erosion with intracoronary thrombus formation 2. Type 2 AMI: Myocardial oxygen supply/demand mismatches due to other causes than an acute coronary plaque rupture or erosion e.g. aortic dissection with involvement of coronary ostia, coronary vasospasm, coronary embolism, coronary vasculitis, coronary microvascular dysfunction, prolonged brady-or tachyarrhythmias, severe anaemia or shock, acute respiratory hypoxia, hypertensive crisis, shock (except septic shock) 3. Acute non-ischemic myocardial injury e.g. cardiac trauma (e. g. contusion, surgery, ablation), myocarditis, cardiotoxic agents 4. Acute indeterminate or multifactorial myocardial injury e.g. acute heart failure unrelated to AMI, acute severe pulmonary embolism, septic shock, severe acute neurological diseases (e.g. ischaemic stroke, haemorrhage) 5. Chronically increased cardiac troponin concentrations Absence of significant a cTn kinetics of elevated values in serial testing differentiates from acute myocardial injury e.g. chronic cardiac diseases, such as severe heart failure, severe aortic valve stenosis or severe coronary artery disease, or chronic renal failure (multifactorial causes) a The definition of significant cardiac troponin I kinetics has been recently extensively reviewed by our group. 41, 42 AMI: acute myocardial infarction; cTn: cardiac troponin.
Thus, there is a lack of confirmation of cardiac injury by cardiac MRI in a significant proportion of patients, and this clinical scenario of difficult to explain cTn elevations will undoubtedly become worse with the introduction of cTn assay with very high analytical sensitivity (so called 'ultra-sensitive') in routine diagnosis. Despite its clinical potential, 11 it also has the possible drawback of unnecessary downstream testing and therapies, which could even harm patients. Thus, with the increasing use of these assays the consideration of alternative mechanisms of cTn elevations, apart from myocardial necrosis, is probably becoming more relevant clinically. For example, it has already been suggested that the standard definition of unstable angina as myocardial ischaemia in the absence of evidence for myocardial necrosis, including normal cardiac biomarkers, 44 may have to be adopted, 45 considering the fact that patients with chronic stable CAD may have elevated cTn concentrations when cTn is measured with assays with very high analytical sensitivities. 17 Therefore, the assessment of cTn kinetics in serial testing will become even more important to differentiate chronic from acute myocardial injury. 41, 42 In addition, as indicated above, normal subjects and even healthy athletes show cTn increases in association with heavy endurance exercise. Individuals performing such heavy physical activities regularly, therefore, should not be included in future cTn normal range studies for cTn assays with high analytical sensitivity. As a further example, consider an individual with hypertension and left ventricular hypertrophy who has a baseline value for hs-cTn near the upper reference limit (URL). His postoperative cTn values could easily exceed the URL with a small to modest increase in response to volume expansion and/or catecholamine treatment, which could be consistent with a normal response. If this is true, we should not consider such increases to be clinically relevant. Indeed, in this example suggested, it may be that the cTn baseline concentrations are more relevant for risk stratification similar to exercise stress testing in patients with stable CAD. 13 In addition, it is conceivable, irrespective of the aetiology of cTn release, that either repetitive insults, an abnormal cardiac substrate or abnormal myocardial renewal processes might be capable of transforming these stimuli into a pathophysiologically relevant process, for example, chronic cardiac abnormalities seen in some elite athletes or the relationship between exercise and, for example, arrhythmogenic right ventricular dysplasia or myocardial fibrosis and prognosis in endurance athletes. [8] [9] [10] 18 Conclusions cTn elevations, which are difficult to explain clinically, are increasingly seen with the widespread use of cTn assays with high analytical sensitivity. However, after ruling out myocardial injury by imaging techniques including cardiac MRI and analytical interferences of the applied cTn assay clinicians may be confronted with patients without evidence for myocardial necrosis apart from an increased cTn concentration. Some argue that the currently available imaging technologies are less sensitive than the cTn assays with high analytical sensitivities. However, there is also experimental evidence for alternative mechanisms of cTn release apart from myocardial necrosis. Whether cTn can be released from reversibly injured cardiomyocytes still remains one of the most controversial topics in the field of cardiac biomarkers. There is some evidence to conclude that cTn increases could come from reversibly injured cardiomyocytes, but given the limitations of currently available imaging modalities this is still very difficult to prove in humans. Despite the fact that in the vast majority of patients, myocardial necrosis is the cause of cTn increase, one should be cautious in using cTn increases as direct proof of myocardial necrosis, particularly when detecting only modest elevations above the URL. Cardiomyocytes might die also because of enhanced apoptosis. The extent to which these alternative mechanisms of cTn release contribute to small hs-cTn elevations which are seen in daily clinical practice still remains to be shown more definitively, but this should be an area of further future investigation. With increasing cTn concentrations, the likelihood of myocardial necrosis increases. Diseases with delayed biomarker clearance (e.g. renal failure) may also lead to chronically, mildly increased cTn concentrations in blood. Finally, however, it has to be stressed that regardless of the mechanisms underlying increased cTn concentrations, the prognostic significance of increased cTn concentrations has been proven, and careful clinical work-up is required in all these patients.
